Related references
Note: Only part of the references are listed.TRANSCEND FL: PHASE 2 STUDY RESULTS OF LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)
F. Morschhauser et al.
HEMATOLOGICAL ONCOLOGY (2023)
Epcoritamab + R2 regimen and responses in high-risk follicular lymphoma, regardless of POD24 status.
Reid Merryman et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
A phase 2 trial of mosunetuzumab with lenalidomide augmentation as first-line therapy for follicular (FL) and marginal zone lymphoma (MZL).
Adam J Olszewski et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia
Barbara Eichhorst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2023)
Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities
Anna Maria Frustaci et al.
CANCERS (2023)
Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study
Emmanuel Bachy et al.
BLOOD (2022)
CAR T-cell therapy for B-cell lymphoma
Nathan Denlinger et al.
CURRENT PROBLEMS IN CANCER (2022)
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
Caron A. Jacobson et al.
LANCET ONCOLOGY (2022)
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
Nathan Hale Fowler et al.
NATURE MEDICINE (2022)
Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma
Ann-Marie E. Broeske et al.
BLOOD ADVANCES (2022)
The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint
Nicholas C. Richardson et al.
LANCET ONCOLOGY (2022)
Tazemetostat in relapsed/refractory follicular lymphoma: a propensity score-matched analysis of E7438-G000-101 trial outcomes
David G. Proudman et al.
Oncotarget (2022)
Odronextamab, a human CD20xCD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial
Rajat Bannerji et al.
LANCET HAEMATOLOGY (2022)
CELESTIMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma who have received ≥ 1 line of systemic therapy.
Loretta J. Nastoupil et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma
Franck Morschhauser et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Subcutaneous epcoritamab with rituximab + lenalidomide (R2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial.
Lorenzo Falchi et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
Lihua E. Budde et al.
LANCET ONCOLOGY (2022)
Follicular lymphoma: 2023 update on diagnosis and management
Eric Jacobsen
AMERICAN JOURNAL OF HEMATOLOGY (2022)
CAR-T for follicular lymphoma: are we good to go?
Robin Gasiorowski et al.
BLOOD (2022)
Biological and clinical significance of epigenetic alterations in B-cell lymphomas
Daisuke Ennishi
INTERNATIONAL JOURNAL OF HEMATOLOGY (2022)
Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose- escalation, dose-expansion, phase 1-2 study
Alexandre Bazinet et al.
LANCET HAEMATOLOGY (2022)
Efficacy and Safety of Single-Agent Zandelisib Administered By Intermittent Dosing in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Final Results of the Tidal Phase 2 Study
Andrew D. Zelenetz et al.
BLOOD (2022)
Phase 3 Trial of Subcutaneous Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Vs R2 Among Patients with Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)
Lorenzo Falchi et al.
BLOOD (2022)
Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1-3a: Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
Tae Min Kim et al.
BLOOD (2022)
A Phase II Trial of the Combination of Obinutuzumab, Venetoclax, and Ibrutinib in Patients with Previously Untreated Follicular Lymphoma
Tamer Othman et al.
BLOOD (2022)
Five-Year Results and Overall Survival Update from the Phase 3 Randomized Study Augment: Lenalidomide Plus Rituximab (R2) Vs Rituximab Plus Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
John P. Leonard et al.
BLOOD (2022)
Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Franck Morschhauser et al.
BLOOD (2021)
Mosunetuzumab in Combination with Lenalidomide Has a Manageable Safety Profile and Encouraging Activity in Patients with Relapsed/Refractory Follicular Lymphoma: Initial Results from a Phase Ib Study
Franck Morschhauser et al.
BLOOD (2021)
Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-203)
Ryan C. Lynch et al.
BLOOD (2021)
An EZH2 Gene Expression Signature Is Predictive of Differential Efficacy of Chemotherapy Irrespective of EZH2 Mutation Status in Patients with Follicular Lymphoma Treated within the Gallium Trial
Verena Passerini et al.
BLOOD (2021)
Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment
Hilma J. van der Horst et al.
BLOOD CANCER JOURNAL (2021)
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
Martin Hutchings et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial
Matthew J. Matasar et al.
LANCET ONCOLOGY (2021)
Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas
Ross Salvaris et al.
JOURNAL OF PERSONALIZED MEDICINE (2021)
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
Martin Hutchings et al.
LANCET (2021)
PI3K inhibitors are finally coming of age
Bart Vanhaesebroeck et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma A Review
Frederick L. Locke et al.
JAMA ONCOLOGY (2020)
Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study
Martin Dreyling et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma
Nathan H. Fowler et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study
Marie-Helene Delfau-Larue et al.
BLOOD ADVANCES (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
Franck Morschhauser et al.
LANCET ONCOLOGY (2020)
Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma
Constantine S. Tam et al.
BLOOD ADVANCES (2020)
How do I sequence therapy for follicular lymphoma?
Gilles Salles
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2020)
Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy
Rajat Bannerji et al.
BLOOD (2020)
Bispecific Antibodies in the Treatment of Hematologic Malignancies
Johannes Duell et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
John P. Leonard et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study
Emmanuel Bachy et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study
Franck Morschhauser et al.
LANCET HAEMATOLOGY (2019)
Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era
Alfredo Rivas-Delgado et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
A Phase I/II Study of Lenalidomide Plus Obinutuzumab in Relapsed Indolent Lymphoma
Nathan H. Fowler et al.
BLOOD (2019)
Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL
Paolo Strati et al.
BLOOD ADVANCES (2019)
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
F. Morschhauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial
Nancy L. Bartlett et al.
BLOOD (2018)
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
R. Marcus et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The FCGR3A polymorphism predicts the response to rituximab-based therapy in patients with non-Hodgkin lymphoma: a meta-analysis
Duo Liu et al.
ANNALS OF HEMATOLOGY (2016)
Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial
Mathias Rummel et al.
LANCET ONCOLOGY (2016)
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial
Laurie H. Sehn et al.
LANCET ONCOLOGY (2016)
Efficacy and Safety of CTL019 in the First US Phase II Multicenter Trial in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of an Interim Analysis
Shannon L. Maude et al.
BLOOD (2016)
Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies
Liping L. Sun et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys
Eric J. Smith et al.
SCIENTIFIC REPORTS (2015)
Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN
Anita K. Gandhi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers et al.
NATURE MEDICINE (2013)
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
A. Lopez-Girona et al.
LEUKEMIA (2012)
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
Ekkehard Moessner et al.
BLOOD (2010)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Thomas E. Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Share Paper
